Media

TRIANNI and LakePharma Announce Strategic Technology Partnering Agreement

San Francisco and Belmont, CA, USA, {May 9, 2016} – Trianni, Inc., (TRIANNI)  a private biotech company developing novel antibody […]

Continue reading

TRIANNI Announces Issuance of Russian Federation Patent

SAN FRANCISCO, March 2, 2016 — Trianni, Inc. (TRIANNI) announces that key aspects of its human antibody mouse platform were issued […]

Continue reading

TRIANNI Announces BIO Asia International Conference Sponsorship

San Francisco, CA, USA., February 23, 2016 – TRIANNI, Inc. (“Trianni”), a biotechnology company with proprietary antibody discovery technology, announced […]

Continue reading

Achaogen and TRIANNI Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform

San Francisco, CA, and South San Francisco, CA – February 8, 2016 – TRIANNI, Inc. (“TRIANNI”) and Achaogen, Inc. (NASDAQ:AKAO), […]

Continue reading

TRIANNI Announces Issuance of Patent in Australia

Emeryville, CA, USA., Dec 18, 2015 – Trianni, Inc. is delighted to announce that the Trianni Mouse Platform was granted […]

Continue reading

Considerations for Choosing an Antibody Platform

Antibody-based drugs now rival or surpass the small-molecule drugs in terms of effectivity, specificity, minimal side effects, number of ongoing […]

Continue reading

Takeda and TRIANNI Sign Licensing Agreement For Use of TRIANNI Transgenic Mouse Platform

TRIANNI, Inc. (“Trianni”) and Takeda Pharmaceutical Company Limited (“Takeda”) jointly announced today that they have entered into a license agreement […]

Continue reading

TRIANNI Announces Launch of Its Optimized Human Antibody Transgenic Mouse

Emeryville, California – TRIANNI, Inc., a Californian biotechnology company, announced today the launch of its TRIANNI Mouse, a monoclonal antibody […]

Continue reading